# OnCo record nct04198766 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04198766/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04198766", "NCT04198766" ;
  schema:name "Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalen"@en ;
  schema:description "A phase 1/2 trial of Pembrolizumab, Pemetrexed, Gemcitabine in non-small-cell lung cancer and small-cell lung cancer, run by Inhibrx Biosciences, Inc, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04198766/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04198766> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2019-12-10" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/rcc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/gemcitabine/> ;
  onco:companies <https://onco.cc/companies/inhibrx/> .